Rep. Cisneros Sells Healthpeak Properties Shares

Democratic Congressman discloses sale of $1,001 to $15,000 in Healthpeak stock

Mar. 18, 2026 at 12:08am

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Healthpeak Properties, Inc. (NYSE:DOC). In a filing disclosed on March 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Healthpeak Properties stock on February 10th. The trade occurred in the Representative's '150 MAIN STREET TRUST > BANK OF AMERICA' account.

Why it matters

As a member of Congress, Representative Cisneros is subject to financial disclosure rules that require the reporting of stock trades. This sale of Healthpeak Properties shares is noteworthy as it involves a sitting member of Congress and a real estate investment trust focused on the healthcare industry.

The details

Healthpeak Properties, Inc. is a real estate investment trust (REIT) that specializes in healthcare-related real estate, including life science research facilities, medical office buildings, and senior housing communities. The company's stock (NYSE:DOC) has seen some volatility in recent months, with shares trading between $15.71 and $20.81 over the past year.

  • Representative Cisneros disclosed the stock sale on March 9, 2026.
  • The trade occurred on February 10, 2026.

The players

Gilbert Ray Cisneros, Jr.

A Democratic member of the U.S. House of Representatives, representing California's 31st Congressional District. He assumed office in January 2025 and is running for re-election in 2026.

Healthpeak Properties, Inc.

A real estate investment trust (REIT) that specializes in healthcare-related real estate, including life science research facilities, medical office buildings, and senior housing communities.

Got photos? Submit your photos here. ›

The takeaway

This stock trade by a sitting member of Congress highlights the importance of financial transparency and disclosure rules for elected officials. As Healthpeak Properties is a REIT focused on the healthcare industry, the sale also raises questions about potential conflicts of interest or insider knowledge that may have influenced the Representative's decision.